Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Flow cytometric analysis of Human peripheral blood lymphocytes staining with FITC-Labeled Monoclonal Anti-Human CD3 Antibody, Mouse IgG1 (UCHT1) (Cat. No. CD3-FM532) at 1:50 dilution (2 μL of the antibody stock solution corresponds to labeling of 1e6 PBMCs in a final volume of 100 µL), compared with isotype control antibody. FITC signal was used to evaluate the binding activity (QC tested).
Flow cytometric analysis of Human peripheral blood lymphocytes respectively staining with FITC-Labeled Monoclonal Anti-Human CD3 Antibody Mouse IgG2a (Cat. No. FABm001-03) at 1:20 dilution (5 μL of the antibody stock solution corresponds to labeling of 2.5e5 cells in a final volume of 100 µL), compared with isotype control antibody. FITC signal was used to evaluate the binding activity (QC tested).
Immobilized Human CD3E&CD3D Heterodimer Protein (Cat. No. CDD-H52Wa) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human CD3 Antibody, Mouse IgG2a (Clone: OKT3), premium grade (Cat. No. CDE-CH44G1) with a linear range of 0.1-4 ng/mL (QC tested).
The purity of Monoclonal Anti-Human CD3 Antibody, Human IgG4 (Clone: OKT3), premium grade (Cat. No. CDE-CH64G0) is more than 90% and the molecular weight of this protein is around 135-165 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Mouse monoclonal antibody against human CD3 antigen of T lymphocyte (Wuhan Institute of Biological Products) | Approved | Wuhan Institute Of Biological Products Co Ltd | Mainland China | Rejection of organ transplantation | Wuhan Institute Of Biological Products Co Ltd | 1999-01-01 | Rejection of organ transplantation | Details | ||
| Tebentafusp | ImmTAC-gp-100; IMC-gp-100; IMC-gp100 | Approved | Immunocore Ltd | KIMMTRAK | United States | Uveal melanoma | Immunocore Ltd | 2022-01-25 | Skin Melanoma; Liver Neoplasms; Uveal melanoma; Melanoma | Details |
| Odronextamab | REGN-1979 | Approved | Regeneron Pharmaceuticals Inc | ORDSPONO | EU | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Regeneron Pharmaceuticals Inc | 2024-08-26 | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Teclistamab | JNJ-64007957; JNJ-64007959; JNJ-7957 | Approved | Genmab A/S, Johnson & Johnson Innovative Medicine | TECAYLI, TECVAYLI, 泰立珂 | EU | Multiple Myeloma | Janssen-Cilag International Nv | 2022-08-23 | Hematologic Diseases; Immunoglobulin Light-chain Amyloidosis; Smoldering Multiple Myeloma; Multiple Myeloma | Details |
| Teplizumab | PRV-031; MGA-031; hOKT3-gamma-1-ala-ala; hOKT3-γ1-ala-ala | Approved | Tolerance Therapeutics Inc | TZIELD | United States | Diabetes Mellitus, Type 1 | Provention Bio Inc | 2022-11-17 | Diabetes Mellitus, Type 1; Rejection of renal transplantation; Glucose Intolerance; Hypoglycemia; Psoriasis; Diabetes Mellitus, Experimental | Details |
| Mosunetuzumab | RG-7828; BTCT-4465A; RO-7030816; CD20-TBD | Approved | Genentech Inc | Lunsumio | EU | Lymphoma, Follicular | Roche Registration Gmbh | 2022-06-03 | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lupus Erythematosus, Systemic; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Epcoritamab | GEN-3013; ABBV-GMAB-3013 | Approved | Genmab A/S, Abbvie Inc | Tepkinly, TEPKINLY, EPKINLY | United States | Lymphoma, Large B-Cell, Diffuse | Genmab Us Inc | 2023-05-19 | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Richter's Syndrome; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Blinatumomab | BiTE-MT-103; bscCD19xCD3; AMG-103; MT-103; MEDI-538 | Approved | Micromet Inc | Blincyto, 倍利妥 | United States | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Amgen Inc | 2014-12-03 | Leukemia; Neoplasm, Residual; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Recombinant Anti-EpCAM and Anti-CD3Human-mouse Chimeric Bispecific Antibody for Injection (Wuhan Yzy Biopharma Co Ltd) | M-701 | Phase 3 Clinical | Wuhan Yzy Biopharma Co Ltd | Ovarian Neoplasms; Solid tumours; Hydrothorax; Stomach Neoplasms; Neoplasms; Ascites; Colorectal Neoplasms; Pleural Effusion, Malignant; Carcinoma, Non-Small-Cell Lung | Details |
| CD3 and B-cell maturation antigen T-cell engaging bispecific antibody (AbbVie/TeneoOne) | ABBV-383; TNB-383B | Phase 3 Clinical | TeneoOne Inc | Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma | Details |
| Brenetafusp | PRAME HLA-A02; IMC-F106C | Phase 3 Clinical | Immunocore Ltd | Solid tumours; Melanoma | Details |
| Xaluritamig | AMG-509 | Phase 3 Clinical | Xencor Inc, Amgen Inc | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Castration-Sensitive Prostate Neoplasms | Details |
| AZD-0486 | TNB-486; AZD-0486; AZD0486 | Phase 3 Clinical | Teneobio Inc | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Lymphoma, Follicular; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Anti-CD3/humanized 3F8 bispecific antibody-activated T lymphocytes (University of Virginia) | Phase 2 Clinical | University Of Virginia | Neuroblastoma | Details | |
| Foralumab | NI-0401/α-CD3; TZLS-401; NI-0401 | Phase 2 Clinical | Novimmune Sa, Medarex Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Lower Respiratory Tract Infections; Coronavirus Disease 2019 (COVID-19); Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Alzheimer Disease; Cognitive Dysfunction; Dementia; Crohn Disease | Details |
| GNR-084 | GNR-084 | Phase 2 Clinical | Generium Pharmaceuticals, Iontas | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Anti-CD3 and anti-HER2 BiTE-expressing T cell (MedImmune) | Phase 2 Clinical | University Of Michigan, Huazhong University Of Science And Technology, University Of Virginia Cancer Center, Medimmune | Breast Neoplasms | Details | |
| Vibecotamab | XmAb-14045 | Phase 2 Clinical | Xencor Inc | Leukemia, Myeloid; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
| α/β CD3+/CD19+ cell depleted stem cell therapy (New York Medical College) | Phase 2 Clinical | New York Medical College | Leukemia; Anemia; Thalassemia; Hodgkin Disease; Anemia, Aplastic; Lymphoma, Non-Hodgkin; Thrombocytopenia; Kostmann Syndrome; Anemia, Sickle Cell | Details | |
| MK-6070 | HPN-328; MK-6070 | Phase 2 Clinical | Harpoon Therapeutics | Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine | Details |
| Cibisatamab | CEA-TCB; RG-7802; RO-6958688; CEA-CD3 TCB | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh) | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid), University Of Pittsburgh | Primary Immunodeficiency Diseases; Female Urogenital Diseases; Inflammation | Details | |
| MBS-303 | MBS-303 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| HBM-7022 | HBM-7022; AZD-5863 | Phase 2 Clinical | Harbour Biomed | Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms; Esophageal adenocarcinoma; Carcinoma, Pancreatic Ductal | Details |
| TAK-280 | MVC-280; TAK-280 | Phase 2 Clinical | Maverick Therapeutics Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
| GB-261 | CND261; CND-261; GB-261 | Phase 2 Clinical | Genor Biopharma Co Ltd | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| SAR-446309 | AMX-818; HER2-XPAT; SAR-446309; VIR-5818 | Phase 2 Clinical | Amunix Pharmaceuticals Inc | Solid tumours; Neoplasms | Details |
| REGN-5459 | REGN-5459 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma; Renal Insufficiency, Chronic | Details |
| VNX-101 Gene Therapy (Vironexis Biotherapeutics) | VNX-101 | Phase 2 Clinical | Vironexis Biotherapeutics Inc | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| BCD-248 | BCD-248 | Phase 2 Clinical | BIOCAD JSC | Multiple Myeloma | Details |
| Anti-CD3 x Anti-EGFR Bispecific Antibody (EGFRBi) Armed Fresh Peripheral Blood Mononuclear Cells therapy(University Of Virginia) | Phase 2 Clinical | University Of Virginia | Pancreatic Neoplasms | Details | |
| CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells therapy(Institute Of Hematology & Blood Diseases Hospital) | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Lymphoma, B-Cell | Details | |
| MDX-2001 | MDX-2001; MDX2001 | Phase 2 Clinical | ModeX Therapeutics Inc | Kidney Neoplasms; Biliary Tract Neoplasms; Head and Neck Neoplasms; Esophageal Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Thyroid Neoplasms; Endometrial Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| IBI-3003 | IBI3003; IBI-3003 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Multiple Myeloma | Details |
| MBS-314 | MBS-314 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Multiple Myeloma | Details |
| Obrixtamig | BI-764532; OBT620 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Small Cell Lung Carcinoma; Neoplasms; Neuroendocrine Tumors; Carcinoma, Neuroendocrine; Glioma | Details |
| IMC-R117C | IMC-R-117-C | Phase 2 Clinical | Immunocore Holdings PLC | Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms | Details |
| GEN3017 | GEN-3017 | Phase 2 Clinical | Genmab A/S | Hematologic Neoplasms; Hodgkin Disease; Lymphoma, Non-Hodgkin | Details |
| MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
| CD30 biAb-AATC(The Medical College Of Wisconsin Nonprofit) | Phase 2 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, B-Cell; Leukemia; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Lymphoma; Lymphoma, T-Cell, Cutaneous | Details | |
| APVO-436 | APVO-436; APVO436 | Phase 2 Clinical | Aptevo | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| Emfizatamab | GNC-038 | Phase 2 Clinical | SystImmune | Solid tumours; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Central Nervous System Lymphoma | Details |
| CMD-011 | CMD-011 | Phase 2 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
| YK-012 | YK012 | Phase 2 Clinical | Excyte Biopharma Ltd | Lymphoma, B-Cell; Nephrosis; Lupus Erythematosus, Systemic; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
| GEN-1047 | GEN-1047 | Phase 2 Clinical | Genmab A/S | Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| REGN-4336 | REGN-4336 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| GR-1803 | GR-1803 | Phase 2 Clinical | Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd | Multiple Myeloma | Details |
| CM-350 | CM-350 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Solid tumours | Details |
| 1-A-46 | BR-110; 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110 | Phase 2 Clinical | Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, BioRay Pharmaceutical Co Ltd | Lymphoma, B-Cell; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
| LBL-034 | LBL-034 | Phase 2 Clinical | Nanjing WeiLibo biological Technology Co Ltd | Neoplasms; Multiple Myeloma | Details |
| LBL-033 | LBL-033 | Phase 2 Clinical | Nanjing WeiLibo biological Technology Co Ltd | Neoplasms | Details |
| CM-336(Connaught Biomedical Technology) | CM-336; OM336 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Multiple Myeloma | Details |
| ICP-B02 | CM-355; ICP-B02 | Phase 2 Clinical | Beijing Tiannuo Jiancheng Pharmaceutical Technology Co Ltd, Keymed Biosciences Co Ltd | Hematologic Neoplasms; Hematoma; Lymphoma; Lymphoma, Non-Hodgkin | Details |
| SMET-12 | SMET-12 | Phase 2 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| TQB-2825 | TQB-2825 | Phase 2 Clinical | Wuxi Biologics Co Ltd | Lymphoma, B-Cell, Marginal Zone; Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell | Details |
| QLS-31905 | QLS-31905 | Phase 2 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| Nebratamig | GNC-035 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| TAK-186 | EGFR x CD3 COBRA; MVC-101; TAK-186 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| EMB-06 | EMB-06; EMB06; CN106; CND106; CND-106 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Multiple Myeloma; Pemphigus | Details |
| BNT-142 | BNT-142 | Phase 2 Clinical | Biontech Se | Solid tumours | Details |
| CN-201 | CN-201 | Phase 2 Clinical | Curon Biopharmaceutical Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
| ZG006 | ZG006; ZG-006 | Phase 2 Clinical | Gensun Biopharma Inc, Suzhou Zelgen Biopharmaceuticals Co Ltd | Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Carcinoma, Neuroendocrine | Details |
| EX-103 | EX-103; EX103 | Phase 2 Clinical | Guangzhou Excelmab Inc | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Anti-CD3 monoclonal antibody (Jinan Tiankang Biological Products) | Phase 2 Clinical | Jinan Tiankang Biological Products Co Ltd | Anemia, Aplastic | Details | |
| Cevostamab | RG-6160; BFCR-4350A; RO-7187797 | Phase 2 Clinical | Genentech Inc | Multiple Myeloma | Details |
| Anti-CD3/anti-EGFR -activated T cells (Barbara Ann Karmanos Cancer Institute) | Phase 2 Clinical | Barbara Ann Karmanos Cancer Institute, University Of Virginia | Glioblastoma; Pancreatic Neoplasms | Details | |
| Ubamatamab | REGN-4018 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Ovarian Neoplasms; Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms | Details |
| Anti-CD3-anti-HER2-activated T cells | Phase 2 Clinical | Transtarget | Bone metastases; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Breast Neoplasms | Details | |
| JCAR-014 | JCAR-014; JCAR021 | Phase 2 Clinical | Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute, Juno Therapeutics Inc | Lymphoma, B-Cell; Leukemia; Leukemia, Lymphoid; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Candidiasis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Anaplastic; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| A-319 | A-319 | Phase 1 Clinical | Evive Biotech Ltd | Lymphoma, B-Cell; Lupus Erythematosus, Systemic; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details |
| BCMA TriTAC | HPN-217 | Phase 1 Clinical | Harpoon Therapeutics, Abbvie Inc | Multiple Myeloma | Details |
| Membrane bound ligand T-SIGn virus | NG-348 | Phase 1 Clinical | Akamis Bio Ltd | Neoplasms | Details |
| Flotetuzumab | S-80880; MGD-006; RES-234 | Phase 1 Clinical | Macrogenics Inc | Hematologic Neoplasms; Leukemia; Leukemia, Myelogenous, Chronic; Leukemia, Hairy Cell; Mastocytosis, Systemic; Hodgkin Disease; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute | Details |
| NG-641 | EnAd-FAP-BiTE; EnAd-FAP-Tac; NG-641; NG-aFAP | Phase 1 Clinical | Akamis Bio Ltd, University Of Oxford | Squamous Cell Carcinoma of Head and Neck; Neoplasms, Glandular and Epithelial; Neoplasm Metastasis | Details |
| Imvotamab | IGM-2323 | Phase 1 Clinical | Igm Biosciences Inc | Lymphoma, B-Cell, Marginal Zone; Myositis; Autoimmune Diseases; Lupus Erythematosus, Cutaneous; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Arthritis | Details |
| Vixtimotamab | T-564; AMV-564 | Phase 1 Clinical | Amphivena Therapeutics Inc | Solid tumours; Myelodysplastic Syndromes | Details |
| MGD-014 | MGD-014 | Phase 1 Clinical | Macrogenics Inc | HIV Infections | Details |
| JNJ-63898081 | JNJ-8081; JNJ-63898081 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Neoplasms | Details |
| K-193 | K-193 | Phase 1 Clinical | Beijing Lvzhu Biological Technology Co Ltd | Lymphoma, B-Cell | Details |
| Anti-EGFR-bispecific antibody armed activated T-cell therapy (Memorial Sloan Kettering Cancer Center) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Pancreatic Neoplasms | Details | |
| Runimotamab | BTRC-4017A; RG-6194; RO-7227780 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours | Details |
| Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center | Phase 1 Clinical | Roger Williams Medical Center | Prostatic Neoplasms | Details | |
| ONO-4685 | ONO-4685 | Phase 1 Clinical | Merus Nv | Lymphoma, T-Cell; Plaque psoriasis; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| M-802(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | M-802 | Phase 1 Clinical | Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Breast Neoplasms | Details |
| Emirodatamab | AMG-427 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute | Details |
| JNJ-63709178 | JNJ-9178; CNTO-9958; JNJ-63709178 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine, Genmab A/S | Leukemia, Myeloid, Acute | Details |
| SAR-442257 | SAR-442257 | Phase 1 Clinical | Sanofi | Neoplasms | Details |
| CC-1 | CC-1 | Phase 1 Clinical | University Of Tubingen, German Cancer Research Center (Dkfz) | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Squamous Cell | Details |
| Acapatamab | AMG-160 | Phase 1 Clinical | Amgen Inc | Prostatic Neoplasms, Castration-Resistant; Carcinoma, Non-Small-Cell Lung | Details |
| Alnuctamab | CC-93269; EM-901; BMS-986349 | Phase 1 Clinical | Engmab Ag | Multiple Myeloma | Details |
| Pavurutamab | AMG-701 | Phase 1 Clinical | Amgen Inc | Multiple Myeloma | Details |
| HPN-536 | HPN-536 | Phase 1 Clinical | Harpoon Therapeutics | Neoplasms | Details |
| CC-3 | CC-3 | Phase 1 Clinical | Eberhard Karls University Of Tubingen, Germany | Colorectal Neoplasms; Gastrointestinal Neoplasms | Details |
| JS-203 | JS-203 | Phase 1 Clinical | Shanghai Junshi Biological Engineering Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| BC-004 | BC-004 | Phase 1 Clinical | Shandong Buchang Pharmaceuticals Co Ltd | Solid tumours; Breast Neoplasms | Details |
| JY-016 | JY-016 | Phase 1 Clinical | Beijing Jingyitaixiang Technology Development Co Ltd, Beijing Eastern Biotech Co Ltd | Solid tumours; Colorectal Neoplasms; Lung Neoplasms | Details |
| EX-105 | EX-105; EX105 | Phase 1 Clinical | Guangzhou Excelmab Inc | Solid tumours | Details |
| EMB-07 | EMB-07 | Phase 1 Clinical | Shanghai Epimab Biotherapeutics, Inc | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Adenocarcinoma of Lung; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Lymphoma; Uterine Neoplasms | Details |
| BA-3182 | BA-3182 | Phase 1 Clinical | Bioatla | Solid tumours; Adenocarcinoma | Details |
| BA-1202 | BA-1202 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Solid tumours | Details |
| NexGem | CLN-978 | Phase 1 Clinical | Adimab LLC | Lupus Erythematosus, Systemic; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
| MGD-024 | MGD-024 | Phase 1 Clinical | Macrogenics Inc | Leukemia, Myelogenous, Chronic; Leukemia, Hairy Cell; Hodgkin Disease; Myelodysplastic Syndromes; Neoplasms; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, B-Cell; Leukemia, Myeloid, Acute | Details |
| Cabotamig | ARB-202 | Phase 1 Clinical | Arbele Corp | Liver Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal adenocarcinoma; Gastrointestinal Neoplasms | Details |
| CX-904 | CX-904 | Phase 1 Clinical | Amgen Inc, Cytomx Therapeutics Inc | Solid tumours; Neoplasms | Details |
| CLN-049 | CLN-049 | Phase 1 Clinical | University Of Tubingen, German Cancer Research Center (Dkfz) | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| XmAb-819 | XmAb-819 | Phase 1 Clinical | Xencor Inc | Kidney Neoplasms; Carcinoma, Renal Cell | Details |
| NILK-2301 | NILK-2301; NI-2301 | Phase 1 Clinical | Novimmune Sa | Solid tumours; Colorectal Neoplasms | Details |
| BGB-B455 | BGB-B455 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours | Details |
| ABO-2203 | ABO2203; ABO-2203 | Phase 1 Clinical | Ruijin Hospital | Autoimmune Diseases | Details |
| JNJ-70218902 | JNJ-70218902 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Solid tumours; Neoplasms; Myelodysplastic Syndromes; Prostatic Neoplasms, Castration-Resistant; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| APTN-101 | APTN 101 | Phase 1 Clinical | Adaptin Bio | Glioblastoma | Details |
| ALPS-12 | ALPS12; RG6524; RG-6524; ALPS 12 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd | Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine | Details |
| GS-8588 | GS-8588 | Phase 1 Clinical | Gilead Sciences Inc | HIV Infections | Details |
| GNC-077 | GNC-077; GNC077 | Phase 1 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd | Solid tumours; Breast Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms | Details |
| Mesothelin x CD3 Bispecific Antibody(Integral Molecular) | LNK-101; CT-95; LNK101 | Phase 1 Clinical | Integral Molecular Inc | Solid tumours; Pancreatic Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Mesothelioma; Cholangiocarcinoma; Neoplasm Metastasis | Details |
| CM-380 | CM380; CM-380 | Phase 1 Clinical | Keymed Biosciences Co Ltd | Multiple Myeloma | Details |
| QL-335 | QL335; QL-335 | Phase 1 Clinical | Qlsf Biotherapeutics Inc | Colorectal Neoplasms | Details |
| LNF-2007 | LNF2007; LNF-2007 | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Solid tumours | Details |
| QL-325 | QL-325 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd, Qlsf Biotherapeutics Inc | Leukemia, Myeloid, Acute | Details |
| JNJ-67571244 | JNJ-67571244; JNJ-67371244; JNJ-1244 | Phase 1 Clinical | Johnson & Johnson | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| CTIM-76 | CTIM-76 | Phase 1 Clinical | Integral Molecular Inc | Ovarian Neoplasms; Solid tumours; Neoplasms; Testicular Neoplasms; Endometrial Neoplasms | Details |
| YKST-02 | YKST02; YKST-02 | Phase 1 Clinical | Excyte Biopharma Ltd | Multiple Myeloma | Details |
| SCTB-35 | SCTB35; SCTB-35 | Phase 1 Clinical | SinoCelltech Ltd | Lymphoma, B-Cell; Autoimmune Diseases; Lupus Erythematosus, Systemic | Details |
| JNJ-87890387 | JNJ-87890387 | Phase 1 Clinical | Janssen Research & Development Llc | Solid tumours | Details |
| XmAb-541 | XmAb541; XmAb-541 | Phase 1 Clinical | Xencor Inc | Ovarian Neoplasms; Ovarian germ cell tumor; Endometrial Neoplasms; Germinoma; Neoplasms, Germ Cell and Embryonal | Details |
| [89Zr]Zr-BI-764532 | Phase 1 Clinical | C.H. Boehringer Sohn Ag & Co. Kg, Boehringer Ingelheim Gmbh | Small Cell Lung Carcinoma; Carcinoma, Neuroendocrine | Details | |
| TGI-6 | TGI-6 | Phase 1 Clinical | Hefei TG ImmunoPharma Co Ltd | Solid tumours; Colorectal Neoplasms | Details |
| SIM-0500 | SIM0500; SIM-0500 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Bone Marrow Neoplasms; Multiple Myeloma | Details |
| Recombinant anti BCMA/CD3 bispecific antibody(Hualan Genetic Engineering) | Phase 1 Clinical | Hualan Genetic Engineering (Henan) Co Ltd | Multiple Myeloma | Details | |
| Oncolytic Virus R130（Yunying Medical） | R130; R-130; R-130-OV | Phase 1 Clinical | Shanghai Yunying Medical Technology Co Ltd | Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Melanoma; Pharyngeal Neoplasms; Laryngeal Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Bone Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Peritoneal Neoplasms; Sarcoma; Osteosarcoma; Kidney Neoplasms; Breast Neoplasms; Otorhinolaryngologic Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Nose Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma; Solid tumours; Liver Neoplasms; Carcinoma, Bronchogenic; Ovarian Neoplasms; Head and Neck Neoplasms | Details |
| QLS-32015 | QLS-32015; QLS32015 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Multiple Myeloma | Details |
| SAIL-66 | SAIL-66; SAIL66 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd | Solid tumours | Details |
| IMC-P115C | IMC-P-115-C; PRAME-HLE-A02 | Phase 1 Clinical | Immunocore Holdings PLC | Ovarian Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Sarcoma, Synovial; Sarcoma, Endometrial Stromal; Carcinoma, Adenoid Cystic; Cholangiocarcinoma; Endometrial Neoplasms; Uterine Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| BR-115 | CMG6A19; BR115; BR-115; CMG-6-A-19 | Phase 1 Clinical | Chengdu Chimagen Biosciences Co Ltd | Solid tumours | Details |
| OBT620 | OBT620 | Phase 1 Clinical | Boehringer Ingelheim Gmbh, Oxford Biotherapeutics Ltd | Small Cell Lung Carcinoma | Details |
| CBA-1535 | CBA-1535 | Phase 1 Clinical | Chiome Bioscience Inc | Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung | Details |
| JANX-008 | EGFR-TRACTr; JANX008; JANX-008 | Phase 1 Clinical | Janux Therapeutics Inc | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
| ZW-171 | ZW-171 | Phase 1 Clinical | Zymeworks Inc | Solid tumours; Neoplasms | Details |
| JANX-007 | JANX-007; PSMA-TRACTr | Phase 1 Clinical | Janux Therapeutics Inc | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| TQB-2934 | TQB2934; TQB-2934 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Multiple Myeloma | Details |
| JNJ-80948543 | JNJ-80948543 | Phase 1 Clinical | Janssen Research & Development Llc | Lymphoma, B-Cell; Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| PIT-565 | PIT-565 | Phase 1 Clinical | Novartis Pharma Ag | Lymphoma, B-Cell; Neoplasms; Lupus Erythematosus, Systemic; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| CC-312 | CC-312 | Phase 1 Clinical | CytoCares (Shanghai) Inc | Hematologic Neoplasms; Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| ASP-2138 | ASP-2138 | Phase 1 Clinical | Astellas Pharma Global Development Inc, Xencor Inc | Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| ISB-2001 | ISB-2001 | Phase 1 Clinical | Ichnos Sciences Sa | Multiple Myeloma | Details |
| GR-1901 | GR1901; GR-1901 | Phase 1 Clinical | Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details |
| QLS-31904 | QLS31904; QLS-31904 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| RO-7428731 | RO-7428731; RG-6156 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Glioblastoma | Details |
| NM32-2668 | NM-32-2668 | Phase 1 Clinical | Numab Therapeutics Ag | Leiomyosarcoma; Carcinoma, Renal Cell; Esophageal Neoplasms; Adenocarcinoma of Lung; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Neoplasms; Liposarcoma; Mesothelioma; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Adenocarcinoma; Melanoma | Details |
| GBR-1342 | GBR-1342; ISB-1342 | Phase 1 Clinical | Glenmark Pharmaceuticals Ltd | Multiple Myeloma | Details |
| Recombinant humanized anti-CD19/CD3 bispecific antibody(New Time Pharmaceutical) | LNF-1904 | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
| XmAb-968 | XmAb968 | Phase 1 Clinical | Xencor Inc | Hematologic Neoplasms; Leukemia, Promyelocytic, Acute | Details |
| XmAb-18968 | XmAb-18968 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Leukemia, Myeloid, Acute | Details |
| SQZ-622(Novartis Pharma) | SQZ-622 | Phase 1 Clinical | Novartis Pharma Ag | Leukemia, Myeloid, Acute | Details |
| Forimtamig | RG-6234 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
| RG-6232 | RG-6232 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Melanoma | Details |
| RG-6007 | RO-7283420; RG-6007 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Leukemia, Myeloid, Acute | Details |
| SAR-443216 | SAR-443216 | Phase 1 Clinical | Sanofi | Solid tumours; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Lung Neoplasms | Details |
| Recombinant oncolytic type II herpes simplex virus (Binhui Biopharmaceutical) | BS-006; oHSV2-BiTEs; oHSV2CD3-PD-L1 | Phase 1 Clinical | Wuhan Binhui Biotechnology Co Ltd | Solid tumours; Neoplasms; Melanoma; Uterine Cervical Neoplasms | Details |
| JNJ-78306358 | JNJ-78306358; JNJ-6358 | Phase 1 Clinical | Janssen Research & Development Llc | Solid tumours | Details |
| TNB-585 | TNB-585; AMG-340 | Phase 1 Clinical | Teneobio Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| BC-3448 | BC3448; BC-3448 | Phase 1 Clinical | Wuxi BioCity | Solid tumours | Details |
| IBI-389 | IBI-389 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Pancreatic Neoplasms | Details |
| hEGFRvIII-CD3 Bi-scFv | Phase 1 Clinical | Duke University | Glioblastoma; Glioma | Details | |
| JNJ-78278343 | Phase 1 Clinical | Janssen Research & Development Llc | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details | |
| RGV-004 | RGV-004 | Phase 1 Clinical | Hangzhou Rongu Biotechnology Co Ltd | Lymphoma, B-Cell | Details |
| Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical) | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Multiple Myeloma | Details | |
| NVG-111 | NVG-111 | Phase 1 Clinical | NovalGen Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| BI-765049 | BI-765049; OBT-624 | Phase 1 Clinical | Oxford Biotherapeutics Ltd | Solid tumours | Details |
| GNC-039 | GNC-039 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis | Details |
| RO-7425781 | RO-7425781 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
| RO-7293583 | RO-7293583 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Skin Melanoma; Uveal melanoma; Melanoma | Details |
| Rezetamig | JNJ-8780; JNJ75348780; JNJ-75348780 | Phase 1 Clinical | Teneobio Inc | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | Y-150; Y150 | Phase 1 Clinical | Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd | Multiple Myeloma | Details |
| EX-101 | EX-101; EX101 | Phase 1 Clinical | Guangzhou Excelmab Inc | Solid tumours | Details |
| Plamotamab | XmAb-13676 | Phase 1 Clinical | Xencor Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| A-337 | A-337 | Phase 1 Clinical | Evive Biotech Ltd | Solid tumours; Neoplasms | Details |
| CCW-702 | CCW-702 | Phase 1 Clinical | The Scripps Research Institute Inc, Abbvie Inc | Prostatic Neoplasms | Details |
| ERY-974 | ERY-974 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
| PCART7-CD3 | PCART7-CD3 | Clinical | National University Of Singapore | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| InHeAb-01 | InHeAb-01; bsAB | Clinical | University Hospital Tuebingen | Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
